Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) generates a steady flow of news across Innovative Medicine and MedTech, reflecting its role in pharmaceutical preparation manufacturing and medical technologies. On this news page, readers can follow company announcements on clinical trial results, regulatory milestones, strategic transactions, manufacturing investments and corporate actions.
Recent oncology news includes positive topline data from the Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy in relapsed or refractory multiple myeloma, where Johnson & Johnson reported a substantial reduction in the risk of disease progression or death versus standard of care in a population predominantly refractory to anti-CD38 therapy and lenalidomide. The company has also shared longer-term results from the OrigAMI-1 study of RYBREVANT (amivantamab-vmjw) plus chemotherapy in metastatic colorectal cancer, supporting further Phase 3 evaluation of amivantamab-based regimens in first- and second-line settings.
In neuroscience and mental health, Johnson & Johnson has highlighted new data on CAPLYTA (lumateperone), SPRAVATO (esketamine) and the investigational agent seltorexant at major scientific meetings, including analyses focused on remission in major depressive disorder, treatment-resistant depression and sleep-related symptoms. The company has also announced positive Phase 2b results for nipocalimab in systemic lupus erythematosus and plans to initiate a Phase 3 program, underscoring its activity in autoantibody-driven diseases.
MedTech news covers developments such as the FDA submission of the OTTAVA robotic surgical system for De Novo classification, supported by an IDE study in gastric bypass procedures, and an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for chronic subdural hematoma. Corporate and financial updates, including quarterly dividend declarations, U.S. manufacturing investments and government agreements to improve access to medicines, also appear in Johnson & Johnson’s news flow. Investors, clinicians and observers can use this page to monitor how Johnson & Johnson’s clinical, regulatory and strategic decisions evolve over time.
Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 42nd Annual Health Care Virtual Conference on March 7, 2022, at 9:10 a.m. (Eastern Time). Mathai Mammen, Executive VP of Pharmaceuticals R&D, will represent the company. Investors and interested parties can access the conference call via the Johnson & Johnson website. A webcast and podcast replay will be available approximately 48 hours after the live event.
Johnson & Johnson (NYSE: JNJ) will participate in Citi's 2022 Virtual Healthcare Conference on February 23, 2022. The session will feature Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices, presenting at 11:00 a.m. ET. Interested investors can access the conference via the Johnson & Johnson website. Following the live event, a webcast and podcast replay will be available approximately 48 hours later.
Johnson & Johnson (NYSE: JNJ) reported a robust performance for Q4 and full-year 2021. Reported sales reached $24.8 billion in Q4, a 10.4% increase, and $93.8 billion for the year, up 13.6%. Net earnings surged by 172.5% in Q4 to $4.7 billion, while full-year net earnings rose 41.9% to $20.9 billion. Adjusted operational sales growth was notable in Pharmaceuticals (13.6%) and Medical Devices (16.8%), despite supply constraints in Consumer Health. New product approvals and a planned separation of the Consumer Health business were also highlighted as key strategic moves for future growth.
On January 6, 2022, Johnson & Johnson (NYSE: JNJ) released findings from the largest study on COVID-19 vaccine durability in the U.S., highlighting that a single dose of their vaccine provides long-term protection for up to six months. The study, conducted with leading institutions, confirmed an approximately 80% effectiveness against hospitalizations. Notable results included no waning protection against ICU admissions and a modest increase in breakthrough infections after month four. This research positions the Johnson & Johnson vaccine as a viable option amid evolving COVID-19 variants.
Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.06 per share for the first quarter of 2022. This dividend payment is scheduled for March 8, 2022, to shareholders on record as of February 22, 2022, with an ex-dividend date of February 18, 2022. The announcement underscores the company's commitment to returning value to its shareholders while continuing its mission to improve health outcomes globally.
Johnson & Johnson (NYSE: JNJ) reported positive preliminary results from the South African Phase 3b Sisonke study, indicating an 85% effectiveness of its COVID-19 vaccine booster against hospitalization during the Omicron variant surge. The study involved healthcare workers and revealed that vaccine effectiveness increased over time post-boost. Additionally, a separate analysis showed that a heterologous booster regimen significantly enhanced immune responses compared to a homologous booster. These findings underscore the robustness of the Johnson & Johnson vaccine amidst evolving COVID-19 variants.
The CHMP of the EMA issued a Positive Opinion for Johnson & Johnson's COVID-19 vaccine booster, recommending it for adults 18+ at least two months post-initial vaccination. The booster increased protection to 75% against symptomatic COVID-19 and demonstrated 100% protection against severe cases, with data from the Phase 3 ENSEMBLE 2 study. The vaccine was generally well-tolerated, showing no new safety concerns. The recommendation supports its use as a 'mix and match' booster.
Johnson & Johnson (NYSE: JNJ) will hold a conference call on January 25, 2022, at 8:30 a.m. Eastern Time to discuss its fourth-quarter results. The call will feature key executives, including Joaquin Duato, the incoming CEO. Investors can access the call via the company's website and by phone. A replay will be available until February 8, 2022. The earnings report will be released at approximately 6:45 a.m. Eastern Time on the same day. For future events, please visit Johnson & Johnson's investor relations page.
Johnson & Johnson (NYSE: JNJ) received interim recommendations from the WHO's Strategic Advisory Group of Experts (SAGE) supporting its COVID-19 vaccine as a booster shot for individuals 18 and older, to be given 2 to 6 months post the primary vaccination. The booster enhances protection against symptomatic infections and severe disease. The recommendations are based on data from clinical trials and Phase 3 studies. The company is committed to delivering up to 900 million doses to the African Union and COVAX by 2022, ensuring accessibility amid the pandemic.
Johnson & Johnson (NYSE: JNJ) announced key appointments to its Executive Committee, following the retirement of Michael Sneed, effective April 1, 2022. Joaquin Duato will succeed Alex Gorsky as CEO on January 3, 2022. New executive roles include Vanessa Broadhurst as Executive VP of Global Corporate Affairs and Mathai Mammen as Executive VP of Pharmaceuticals, R&D. The leadership changes aim to strengthen company strategy and execution, as highlighted by Duato, who emphasized the team's dedication to the company's mission.